Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses.
Science
; 378(6622): eabo2523, 2022 11 25.
Article
in English
| MEDLINE | ID: covidwho-2088384
ABSTRACT
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has highlighted the need for vaccines that not only prevent disease but also prevent transmission. Parenteral vaccines induce robust systemic immunity but poor immunity at the respiratory mucosa. We developed a vaccine strategy that we call "prime and spike," which leverages existing immunity generated by primary vaccination (prime) to elicit mucosal immune memory within the respiratory tract by using unadjuvanted intranasal spike boosters (spike). We show that prime and spike induces robust resident memory B and T cell responses, induces immunoglobulin A at the respiratory mucosa, boosts systemic immunity, and completely protects mice with partial immunity from lethal SARS-CoV-2 infection. Using divergent spike proteins, prime and spike enables the induction of cross-reactive immunity against sarbecoviruses.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Immunity, Mucosal
/
Spike Glycoprotein, Coronavirus
/
COVID-19 Vaccines
/
SARS-CoV-2
/
COVID-19
/
Memory B Cells
/
Memory T Cells
/
Immunologic Memory
Type of study:
Randomized controlled trials
Topics:
Vaccines
Limits:
Animals
Language:
English
Journal:
Science
Year:
2022
Document Type:
Article
Affiliation country:
Science.abo2523
Similar
MEDLINE
...
LILACS
LIS